Results 11 to 20 of about 5,103,561 (270)
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
David S. Knopman +7 more
openaire +4 more sources
The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later
Grøntvedt, G. +5 more
openaire +5 more sources
Elucidating the role of DEPTOR in Alzheimer's disease [PDF]
This article has been made available through the Brunel Open Access Publishing Fund.The mammalian or mechanistic target of rapamycin (mTOR) is a Ser/Thr protein kinase that, in response to nutrient stimulation, regulates cellular growth, proliferation ...
Karteris, E +3 more
core +7 more sources
Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration. Eponymic diseases of the nervous system such as Alzheimer's, Parkinson's, and Huntington's diseases that were long characterized by mechanistic ignorance have yielded striking progress ...
Adam, Gazzaley, Scott A, Small
+8 more sources
A data-driven examination of apathy and depressive symptoms in dementia with independent replication [PDF]
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or ...
Schuff, N +96 more
core +1 more source
Use of valid diagnostic criteria is extremely important in the recognition of Alzheimer's disease (AD). Patients with mild to moderate Alzheimer's disease should be started on a cholinesterase inhibitor and possibly anti-inflammatory agents, antioxidants (vitamin E or selegiline), and estrogen replacement therapy (for postmenopausal women).
, Schachter, , Davis
+8 more sources
Introduction The study examined Black and White prospective participants’ views of barriers to and facilitators of participation in Alzheimer's disease (AD) biomarker research.
Johanne Eliacin +12 more
doaj +1 more source
Summary: It has been suggested that aberrant activation of glycogen synthase kinase-3-beta (GSK-3β) can trigger abnormal tau hyperphosphorylation and aggregation, which ultimately leads to neuronal/synaptic damage and impaired cognition in Alzheimer ...
Ana Claudia Amaral +15 more
doaj +1 more source
Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis. [PDF]
Annals of Clinical and Translational Neurology, EarlyView.
Ciaccio M, Agnello L.
europepmc +2 more sources
Introduction Acculturation‐related characteristics, that is, factors directly connected to culture and familial relationships, are associated with engaged research participation within Latino communities.
Melissa Lamar +6 more
doaj +1 more source

